RxDoctor Payments Data

Ammar Alsheikh, MD

Internal Medicine · Chandler, AZNPI 1083609515

Payments from drug & device makers

$5,982in general payments, 2019–2025

Across 367 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$968
  • AbbVie$681
  • AstraZeneca$618
  • Lilly USA, LLC$397
  • Boehringer Ingelheim$382
  • GSK$361
  • plus $3K from 51 others

What the payments were for

  • Food & beverage$5,92399%
  • Education$421%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,982 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$384,903
Medicare patients
606
Services billed
4,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$213,781
JardianceEmpagliflozin109$112,116
EliquisApixaban72$95,017
MounjaroTirzepatide46$53,081
JanuviaSitagliptin Phosphate43$47,983
XareltoRivaroxaban23$37,213
FarxigaDapagliflozin Propanediol29$36,396
TrulicityDulaglutide22$35,861
RybelsusSemaglutide18$28,688
Breo ElliptaFluticasone/Vilanterol43$23,103
JanumetSitagliptin Phos/Metformin Hcl12$19,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,648
LinzessLinaclotide14$16,892
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$15,328
VascepaIcosapent Ethyl18$15,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$968$242,469210 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$382$129,595138 claims
PfizerEliquis$212$95,01772 claims
Lilly USA, LLCMounjaro, Trulicity$397$88,94268 claims
MerckJanuvia, Janumet$62$67,07155 claims
GSKBreo Ellipta, Trelegy Ellipta$361$41,75071 claims
Johnson & JohnsonXarelto$43$37,21323 claims
AstraZenecaFarxiga$618$36,39629 claims
AbbVieLinzess, Synthroid$681$22,43786 claims
Sanofi-aventis U.S. LLCLantus$108$6,55037 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$15$4,70311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →